With headquarters and operations spanning the US, Europe, and Korea, our hub-and-spoke model leverages centralized expertise to support a portfolio of innovative subsidiaries. Our people bring a rare mix of deep scientific knowledge, clinical insight, and capital markets experience, enabling disciplined, high-impact decision-making. United by a focus on “simplification through innovation,” we streamline complex therapies, delivery systems, and healthcare processes to make advanced treatments more accessible, efficient, and effective for patients and healthcare systems worldwide.

Learn more about our team here

Hub-and-Spoke Healthcare

With headquarters and operations spanning the US, Europe, and Korea, our hub-and-spoke model leverages centralized expertise to support a portfolio of innovative subsidiaries. Our people bring a rare mix of deep scientific knowledge, clinical insight, and capital markets experience, enabling disciplined, high-impact decision-making. United by a focus on “simplification through innovation,” we streamline complex therapies, delivery systems, and healthcare processes to make advanced treatments more accessible, efficient, and effective for patients and healthcare systems worldwide.

At OSR Health, we target biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control.

We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our platforms currently include:

Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.

Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Noninvasive Glucose Monitoring: A pioneering, truly noninvasive glucose monitor based on NIRS technology.

Medical Device Technologies: Distribution of neurovascular intervention systems in South Korea.

Strategic Portfolio Expansion

At OSR Health, we target biopharmaceuticals that have innovative, proprietary R&D platforms, rather than single assets. By taking 100% ownership in our spoke companies, we maintain full operational and strategic control.

We constantly evaluate M&A opportunities that advance innovative healthcare, whether through addressing unmet patient needs or lowering patient costs and burden. We are focused on portfolio expansion across the U.S., Europe, and Korea. Our platforms currently include:

Immuno-Oncology: Development of oral T-cell activation therapies targeting tumor vasculature and associated structures.
Regenerative Biologics: Design-Augmented (DA) biologics aimed at treating age-related and degenerative diseases.
Noninvasive Glucose Monitoring: A pioneering, truly noninvasive glucose monitor based on NIRS technology.
Medical Device Technologies: Distribution of neurovascular intervention systems in South Korea.

Who is eligible to participate in the Shareholder Loyalty CVR Program?

All shareholders who own OSR Health common stock as of the applicable Record Date are eligible to apply for the Shareholder Loyalty CVR Program. Shareholders must complete the required enrollment process and satisfy the applicable program requirements before Contingent Value Rights (CVRs) are issued.

How do I enroll?

Enrollment is completed by submitting the appropriate application form. U.S. shareholders will need to hold their shares through Direct Registration (DRS) with the Company's transfer agent before enrolling. Non-U.S. shareholders enroll through a separate application process. Full instructions and forms are available on this page.

What happens if I sell my shares?

The Shareholder Loyalty CVR Program is designed to reward long-term ownership. If you sell, transfer, or otherwise dispose of the shares associated with your CVRs before the applicable milestone is achieved, those CVRs will generally terminate and will no longer be eligible to receive additional shares.

Extra shares recieved by reaching are milestones are free to be sold and don't affect future milestone rewards associated with the CVRs from the original shares held on record date.

Do I need to do anything after enrolling?

Once your enrollment has been approved, no further action is generally required. Simply continue to hold your enrolled shares and remain eligible under the terms of the program. If applicable share price milestones are achieved during the program period, eligible U.S. shareholders will receive the corresponding share distributions in accordance with the program terms. Non U.S. shareholders will have to provide a broker attestation on each measurement date to confirm their original shares position.